US 11117973
Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms
granted A61KA61K2039/505A61K39/39558
Quick answer
US patent 11117973 (Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms) held by Inhibrx, Inc. expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Inhibrx, Inc.
- Grant date
- Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 39
- CPC classes
- A61K, A61K2039/505, A61K39/39558, A61P, A61P35/00